These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2008-000225-19 ENSAYO CLÍNICO DE FASE II, MULTICÉNTRICO, ABIERTO, NO CONTROLADO PARA EVALUAR LA EFICACIA DE LA COMBINACIÓN DE SORAFENIB Y BEVACIZUMAB EN EL TRATAMIENTO DE PACIENTES CON TUMOR NEUROENDOCRINO AVANZADO ... not-yet-due
Completed, but no date 2010-020749-28 Ensayo clínico fase II, abierto, no controlado, multicéntrico de pazopanib en monoterapia para la determinación de actividad, seguridad y biomarcadores predictivos en pacientes con progresión de tumo... bad-data
Completed, but no date 2010-023422-20 Estudio en fase II de everolimus, un inhibidor mTOR (de formulación oral), junto con OcteotrideLAR®, en pacientes adultos con tumores neuroendocrinos gastrointestinales avanzados no funcionales y bien... bad-data
Ongoing 2011-001550-29 A Phase II randomized double-blind study of Santostatin LAR in combination with Axitinib versus Placebo in patients with progressive advanced well-differentiated neuroendocrine carcinomas of non-pancr... not-yet-due
Ongoing 2013-000726-66 Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by eve... not-yet-due
Ongoing 2014-003924-34 A phase II trial to assess the activity and safety of Palbociclib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET). not-yet-due
Completed, reported early 2014-004072-30 A phase II trial to assess the activity and safety of TH-302 in combination with sunitinib in patients with well- and moderately-differentiated metastatic pancreatic neuroendocrine tumors (pNET) previ... 2020-01-10 not-yet-due
Ongoing 2015-001467-39 A phase II study to evaluate the safety and efficacy of lenvatinib in patients with advanced grade 1/2 neuroendocrine neoplasmas of pancreatic and extrapancreatic origin. not-yet-due
Completed, report not yet due 2015-005774-37 Phase II study to evaluate efficacy of rechallenge with Sunitinib in Patients with Metastatic Pancreatic Neuroendocrine Tumor (pNETs) well differentiated G1/2 advanced or metastatic who previously fai... 2019-10-23 not-yet-due
Ongoing 2016-002858-20 A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with advanced neuroendocrine neoplasms of gastroenteropancreatic or lung origin (the DUNE trial). not-yet-due
Ongoing 2019-001546-18 A phase II study of Platinum-doublet chemotherapy in combination with nivolumab as first-line treatment, in subjects with unresectable, locally advanced or metastatic G3 Neuroendocrine Neoplasms (NENs... not-yet-due